Mary Hobart, PhD | Psychiatrist.com

Brexpiprazole in Combination with Sertraline and as Monotherapy in PTSD: A Full-Factorial Randomized Clinical Trial

Original Research

Brexpiprazole in Combination with Sertraline and as Monotherapy in PTSD: A Full-Factorial Randomized Clinical Trial

February 19, 2025

In this 10-week study, brexpiprazole in combination with sertraline, but not as monotherapy, demonstrated the potential to be a new efficacious treatment for PTSD.

Mary Hobart, Denise Chang, Nanco Hefting, et al

Effects of Brexpiprazole on Functioning in Schizophrenia

Original Research

Effects of Brexpiprazole on Functioning in Schizophrenia

March 1, 2022

Drawing on 4 RCTs and 2 open-label extension studies of brexpiprazole, this analysis looks at the effects of this medication on functioning both in the short term and over...

Mary Hobart, Christoph U. Correll, Stine R. Meehan, et al

Original Research

Efficacy and Safety of Adjunctive Brexpiprazole in MDD

May 22, 2018

Finding effective treatment for depressed patients who do not adequately respond to antidepressant medications is a frequent challenge for clinicians. Read this article to learn about the efficacy, safety,...

Robert D. McQuade, Aleksandar Skuban, Mary Hobart, et al

Original Research

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

September 23, 2015

Robert D. McQuade, Margaretta Nyilas, William H. Carson, et al

Original Research

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

September 23, 2015

Robert D. McQuade, Margaretta Nyilas, William H. Carson, et al